Genus (LON:GNS) was upgraded by Kepler Capital Markets to a “buy” rating in a research note issued to investors on Thursday. The firm currently has a GBX 2,630 ($34.37) price target on the stock, up from their previous price target of GBX 2,475 ($32.34). Kepler Capital Markets’ price objective indicates a potential upside of 2.49% from the company’s current price.

Several other analysts also recently weighed in on the stock. Peel Hunt downgraded shares of Genus to a “hold” rating in a research report on Friday, October 12th. Liberum Capital restated a “hold” rating and set a GBX 2,400 ($31.36) price objective on shares of Genus in a research report on Thursday, September 6th.

Shares of LON:GNS opened at GBX 2,566 ($33.53) on Thursday. Genus has a twelve month low of GBX 1,652 ($21.59) and a twelve month high of GBX 2,597 ($33.93).

In other news, insider Karim Bitar sold 5,920 shares of Genus stock in a transaction on Monday, September 17th. The shares were sold at an average price of GBX 2,538 ($33.16), for a total value of £150,249.60 ($196,327.71).

About Genus

Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.

Featured Article: Insider Trading – What You Need to Know

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.